| 000 | 01742 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250515103941.0 | ||
| 264 | 0 | _c20080312 | |
| 008 | 200803s 0 0 eng d | ||
| 022 | _a0925-5710 | ||
| 024 | 7 |
_a10.1007/BF02984008 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMiura, Yuji | |
| 245 | 0 | 0 |
_aGraft-versus-myeloma effects in reduced-intensity cord blood transplantation. _h[electronic resource] |
| 260 |
_bInternational journal of hematology _cDec 2007 |
||
| 300 |
_a463-5 p. _bdigital |
||
| 500 | _aPublication Type: Letter | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aBusulfan _xadministration & dosage |
| 650 | 0 | 4 | _aCord Blood Stem Cell Transplantation |
| 650 | 0 | 4 | _aDisease-Free Survival |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aGraft Survival |
| 650 | 0 | 4 |
_aGraft vs Host Disease _xprevention & control |
| 650 | 0 | 4 |
_aGraft vs Tumor Effect _xdrug effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunosuppressive Agents _xadministration & dosage |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMultiple Myeloma _xmortality |
| 650 | 0 | 4 |
_aMyeloablative Agonists _xadministration & dosage |
| 650 | 0 | 4 | _aRemission Induction |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 |
_aTacrolimus _xadministration & dosage |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 | _aTransplantation Conditioning |
| 650 | 0 | 4 | _aTransplantation, Homologous |
| 650 | 0 | 4 |
_aVidarabine _xadministration & dosage |
| 700 | 1 | _aAzuma, Takayuki | |
| 700 | 1 | _aKusumi, Eiji | |
| 700 | 1 | _aMatsumura, Tomoko | |
| 700 | 1 | _aKami, Masahiro | |
| 700 | 1 | _aKomatsu, Tsunehiko | |
| 773 | 0 |
_tInternational journal of hematology _gvol. 86 _gno. 5 _gp. 463-5 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/BF02984008 _zAvailable from publisher's website |
| 999 |
_c17700612 _d17700612 |
||